Last updated 2026-06-18
- Acquired by Pincell srl, Jun 2025
- Went public, Jan 2008
- Raised $8M funding round, Dec 2022
Total raised
$63.9M
Last: 2025-10
Stage
Public
Founded
2003
Headcount
32
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.
With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs.
Funding history · 12 rounds · $63.9M total
2008-01
Undisclosed
2014-09
2015-05
$9.5M
2017-01
$2.9M
2017-08
2017-09
$9.0M
2019-04
2019-07
$16.7M
2021-12
$9.8M
2022-12
$8.0M
2023-09
$1.3M
2025-10
Q&A
- What is the current status of Scinai Immunotherapeutics?
- Scinai Immunotherapeutics was acquired by Pincell srl in June 2025.
- What was Scinai Immunotherapeutics' former name?
- Scinai Immunotherapeutics was formerly known as BiondVax Pharmaceuticals.
- Where is Scinai Immunotherapeutics headquartered?
- Scinai Immunotherapeutics is headquartered in Jerusalem, Israel, specifically at the Jerusalem BioPark, Hadassah Ein Kerem Campus.
- How many employees does Scinai Immunotherapeutics have?
- Scinai Immunotherapeutics has 11-50 employees.
- What is Scinai Immunotherapeutics' primary focus?
- Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products, primarily for the treatment of autoimmune and infectious diseases.
- When was Scinai Immunotherapeutics founded?
- Scinai Immunotherapeutics was founded in July 2003.
- What was the most recent funding event for Scinai Immunotherapeutics?
- In October 2025, Scinai Immunotherapeutics received a grant of $246,000 from the Israel Innovation Authority.
- Who are the key executives at Scinai Immunotherapeutics?
- The key executives at Scinai Immunotherapeutics include Amir Reichman (CEO), Elad Mark (COO), and Tamar Ben-Yedidia, PhD (CSO).
- What is Scinai Immunotherapeutics' total raised capital?
- Scinai Immunotherapeutics has raised a total of $63,937,200 USD.
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B2CB2B
Highlights
1 PatentsVerified
Tags
immunotherapyautoimmune-diseasespharmaceuticalsviral-diseasesbiotechnologytherapeuticsinfectious-diseasedrug-discoverytreatmentsdrug-deliverybiopharmaceuticalvaccinespatientsnanotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | scinai.com/ |
|---|---|
| linkedin.com/company/725313 | |
| facebook.com/ScinaiSCNI | |
| YouTube | youtube.com/@Scinai |
| instagram.com/scinai.immunotherapeutics |
Identifiers & details
| Former names | BiondVax Pharmaceuticals |
|---|---|
| Founded | 2003-7 |
| Employees (exact) | 32 |
| Market cap | $2.3M |
| Status reason | Acquired by Pincell srl on Jun, 2025 |
Acquisitions & public offerings
Acquired by Pincell srl 2025-06
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2022-12 | $8.0M | |||
| 2021-12 | $9.8M | |||
| 2017-09 | $9.0M | |||
| 2015-05 | $9.5M | |||
| 2008-01 |
Radar intelligence
Web history (Wayback)
| Domain | scinai.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|